Medpace Holdings (MEDP) stock plummeted 7.21% to trade at $XXX on Tuesday amid the broader market sell-off. The healthcare company's shares were hit hard during the intraday trading session.
The decline came after Truist Financial analyst Jailendra Singh maintained a Hold rating on Medpace Holdings. While the analyst provided no specific price target, the reiterated Hold stance likely contributed to investor concerns over the company's near-term outlook.
Despite the sell-off, some analysts remain optimistic about Medpace's prospects in the healthcare sector. In separate notes, analysts highlighted Medpace as one of their top healthcare picks alongside companies like Incyte.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.